Akebia Therapeutics. has filed a patent for a novel small molecule inhibitor of PHD, which can be used for the treatment of various diseases including heart, lung, respiratory, liver, kidney, inflammatory bowel disease, ischemic reperfusion injury, and retinopathy of prematurity. The patent claim specifically refers to a compound of Formula (I). GlobalData’s report on Akebia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Akebia Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Akebia Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Akebia Therapeutics's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Small molecule inhibitors of phd

Source: United States Patent and Trademark Office (USPTO). Credit: Akebia Therapeutics Inc

A recently filed patent (Publication Number: US20230295110A1) describes a compound of Formula (I) and its various structures and derivatives. The compound can be substituted with different groups, such as alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, carbonyl, or ether. The patent claims cover a wide range of compounds with different structures and substitutions.

The patent also includes claims for pharmaceutical compositions comprising the compound and a pharmaceutically acceptable excipient. These compositions can be used for treating diseases mediated by PHD (prolyl hydroxylase domain) activity. Examples of such diseases include ischemic reperfusion injuries like stroke, myocardial infarction, and acute kidney injury, as well as inflammatory bowel disease, cancer (including colorectal cancer), liver disease, atherosclerosis, cardiovascular disease, and diseases or conditions of the eye like radiation retinopathy, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and ocular ischemia.

The patent also claims methods for treating these diseases by administering the compound or its pharmaceutically acceptable salt to a subject. The method can be used for treating anemia associated with chronic kidney disease, chronic kidney disease itself, diseases associated with hyperoxia like retinopathy of prematurity and bronchopulmonary dysplasia, respiratory diseases and lung diseases including respiratory viral infections and pulmonary viral infections, injury to and/or failure of organs, and other conditions like acute organ injury and organ failure.

Overall, the patent covers a wide range of compounds and their use in pharmaceutical compositions for the treatment of various diseases mediated by PHD activity.

To know more about GlobalData’s detailed insights on Akebia Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies